{"id":"NCT00067470","sponsor":"BioMarin Pharmaceutical","briefTitle":"Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-09","primaryCompletion":null,"completion":"2004-03","firstPosted":"2003-08-25","resultsPosted":"2009-08-17","lastUpdate":"2009-12-24"},"enrollment":39,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Mucopolysaccharidosis VI"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"N-acetylgalactosamine 4-sulfatase","otherNames":["rhASB"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"rhASB","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to evaluate the ability of rhASB versus placebo to enhance endurance in patients with Mucopolysaccharidosis VI (MPS VI), as evidenced by an increase in the number of meters walked in the 12 minute walk test at Week 24 compared with baseline.","primaryOutcome":{"measure":"Change From Baseline in 12-minute Walk Test at 24 Weeks","timeFrame":"baseline and 24 weeks","effectByArm":[{"arm":"rhASB","deltaMin":109,"sd":154},{"arm":"Placebo","deltaMin":26,"sd":122}],"pValues":[{"comp":"OG000 vs OG001","p":"0.025"}]},"eligibility":{"minAge":"7 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["33874971"],"seeAlso":["http://www.bmrn.com"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":19},"commonTop":["Headache","Pyrexia","Arthralgia","Abdominal pain","Vomiting"]}}